BR112022025019A2 - Fusões heterodiméricas de relaxina e usos das mesmas - Google Patents

Fusões heterodiméricas de relaxina e usos das mesmas

Info

Publication number
BR112022025019A2
BR112022025019A2 BR112022025019A BR112022025019A BR112022025019A2 BR 112022025019 A2 BR112022025019 A2 BR 112022025019A2 BR 112022025019 A BR112022025019 A BR 112022025019A BR 112022025019 A BR112022025019 A BR 112022025019A BR 112022025019 A2 BR112022025019 A2 BR 112022025019A2
Authority
BR
Brazil
Prior art keywords
relaxin
heterodimeric
fusions
treatment
fusion polypeptides
Prior art date
Application number
BR112022025019A
Other languages
English (en)
Portuguese (pt)
Inventor
Sermadiras Isabelle
Anna Papworth Monika
Christiane Paterson Judy
Marie Martin Esther
Ke Peng
Original Assignee
Medimmune Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medimmune Ltd filed Critical Medimmune Ltd
Publication of BR112022025019A2 publication Critical patent/BR112022025019A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/64—Relaxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2221—Relaxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Cardiology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • Hospice & Palliative Care (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
BR112022025019A 2020-06-17 2021-06-16 Fusões heterodiméricas de relaxina e usos das mesmas BR112022025019A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063040250P 2020-06-17 2020-06-17
PCT/EP2021/066309 WO2021255127A1 (en) 2020-06-17 2021-06-16 Heterodimeric relaxin fusions and uses thereof

Publications (1)

Publication Number Publication Date
BR112022025019A2 true BR112022025019A2 (pt) 2022-12-27

Family

ID=76584509

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022025019A BR112022025019A2 (pt) 2020-06-17 2021-06-16 Fusões heterodiméricas de relaxina e usos das mesmas

Country Status (17)

Country Link
US (3) US11795205B2 (cg-RX-API-DMAC7.html)
EP (1) EP4168434A1 (cg-RX-API-DMAC7.html)
JP (2) JP7797423B2 (cg-RX-API-DMAC7.html)
KR (1) KR20230024994A (cg-RX-API-DMAC7.html)
CN (1) CN115916813B (cg-RX-API-DMAC7.html)
AR (1) AR125007A1 (cg-RX-API-DMAC7.html)
AU (3) AU2021290997C1 (cg-RX-API-DMAC7.html)
BR (1) BR112022025019A2 (cg-RX-API-DMAC7.html)
CA (1) CA3186143A1 (cg-RX-API-DMAC7.html)
CL (1) CL2022003578A1 (cg-RX-API-DMAC7.html)
CO (1) CO2023000038A2 (cg-RX-API-DMAC7.html)
CR (1) CR20230015A (cg-RX-API-DMAC7.html)
EC (1) ECSP23002960A (cg-RX-API-DMAC7.html)
IL (1) IL298786A (cg-RX-API-DMAC7.html)
MX (1) MX2022016340A (cg-RX-API-DMAC7.html)
TW (1) TWI899263B (cg-RX-API-DMAC7.html)
WO (1) WO2021255127A1 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023086913A2 (en) 2021-11-11 2023-05-19 Tectonic Therapeutic, Inc. Relaxin-2 fusion protein analogs and methods of using same
JP2025517100A (ja) 2022-05-07 2025-06-03 北京拓界生物医薬科技有限公司 リラキシン又は類似体の融合タンパク質及びその医薬的使用
WO2024015634A2 (en) * 2022-07-15 2024-01-18 Nutcracker Therapeutics, Inc. Mrna therapies including sirp-alpha
IL321288A (en) 2022-12-09 2025-08-01 Astrazeneca Ab Dosing regimens using fusions of relaxin heterodimers
WO2024184206A1 (en) 2023-03-03 2024-09-12 Astrazeneca Ab Pharmaceutical formulation comprising heterodimeric relaxin fusion proteins and uses thereof
EP4713001A2 (en) 2023-05-18 2026-03-25 Tectonic Operating Company, Inc. Relaxin-2 fusion protein analogs and methods of using same

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1355919B1 (en) 2000-12-12 2010-11-24 MedImmune, LLC Molecules with extended half-lives, compositions and uses thereof
US8389475B2 (en) * 2009-08-10 2013-03-05 The Board Of Trustees Of The Leland Stanford Junior University Relaxin analogs
CN103429620B (zh) 2010-11-05 2018-03-06 酵活有限公司 在Fc结构域中具有突变的稳定异源二聚的抗体设计
AU2012280474A1 (en) 2011-07-01 2014-01-16 Bayer Intellectual Property Gmbh Relaxin fusion polypeptides and uses thereof
US9574010B2 (en) * 2011-11-04 2017-02-21 Zymeworks Inc. Stable heterodimeric antibody design with mutations in the Fc domain
AR094147A1 (es) * 2012-12-27 2015-07-15 Bayer Pharma Aktiengellschaft Polipeptidos de fusion con actividad de relaxina y sus usos
DK3107938T3 (da) * 2014-05-28 2022-07-11 Zymeworks Inc Modificerede, antigenbindende polypeptidkonstrukter og anvendelser heraf
US11161891B2 (en) * 2015-12-09 2021-11-02 The Scripps Research Institute Relaxin immunoglobulin fusion proteins and methods of use
WO2018138170A1 (en) * 2017-01-25 2018-08-02 Medimmune, Llc Relaxin fusion polypeptides and uses thereof

Also Published As

Publication number Publication date
JP2026053559A (ja) 2026-03-25
EP4168434A1 (en) 2023-04-26
CN115916813A (zh) 2023-04-04
US20220017591A1 (en) 2022-01-20
JP2023530335A (ja) 2023-07-14
KR20230024994A (ko) 2023-02-21
CN115916813B (zh) 2026-03-24
CA3186143A1 (en) 2021-12-23
AU2024200074B2 (en) 2025-11-27
AU2025252658A1 (en) 2025-11-13
JP7797423B2 (ja) 2026-01-13
IL298786A (en) 2023-02-01
US20240025958A1 (en) 2024-01-25
AU2021290997A1 (en) 2023-02-09
US12187774B2 (en) 2025-01-07
AR125007A1 (es) 2023-05-31
MX2022016340A (es) 2023-01-24
CL2022003578A1 (es) 2023-06-09
US11795205B2 (en) 2023-10-24
ECSP23002960A (es) 2023-03-31
US20250230214A1 (en) 2025-07-17
AU2021290997C1 (en) 2024-01-04
TWI899263B (zh) 2025-10-01
CR20230015A (es) 2023-02-17
CO2023000038A2 (es) 2023-01-16
AU2024200074A1 (en) 2024-01-25
AU2021290997B2 (en) 2023-10-12
TW202214673A (zh) 2022-04-16
WO2021255127A1 (en) 2021-12-23

Similar Documents

Publication Publication Date Title
CO2023000038A2 (es) Fusiones heterodiméricas de relaxina y usos de las mismas
CL2022000300A1 (es) Muteínas de interleucina 21 y sus usos para tratar tumores sólidos (divisional de la solicitud no. 202000252)
BR112022027096A2 (pt) Composições e métodos relacionados a agentes terapêuticos ativáveis
BR112012006501A8 (pt) Polipeptídios e usos dos mesmos
BR112021024786A2 (pt) Construção de rna, sequência de ácido nucleico, cassete de expressão, vetor recombinante, composição farmacêutica, método para preparar a construção de rna, vacina, método para modificar uma célula ex vivo ou in vitro e célula modificada
BRPI0508455A (pt) muteìnas de interleucina-2 combinatórias
BR112019010250A2 (pt) novas proteínas klotho recombinantes e composições e métodos que envolvem as mesmas
MX2022010175A (es) Proteinas de union a flt3 y metodos de uso.
BR112022008201A2 (pt) Degradação de proteínas de superfície usando agente de ligação biespecífico
ECSP088262A (es) Proteínas de fusión de albúmina
Yang et al. A novel strategy for the discrimination of gelatinous Chinese medicines based on enzymatic digestion followed by nano-flow liquid chromatography in tandem with orbitrap mass spectrum detection
Wahby et al. Egyptian horned viper Cerastes cerastes venom hyaluronidase: Purification, partial characterization and evidence for its action as a spreading factor
BRPI0720879A2 (pt) microvesícula derivada de fermento carreador de fator de tecido (tf), composição e composição farmacêutica que a compreende, processos para a sua manufatura, proteína lipida de fator de tecido (tf) modificado, polinucleotídeo, vetor, célula hospedeira e anticorpo.
BR112015019729A2 (pt) composição inibidora da il-1b e uso da mesma
JP6943894B2 (ja) 抽出物及び該抽出物を含有する製剤
BR112017021016A2 (pt) preparação de proteína, composição farmacêutica, proteína de fusão, polinucleotídeo isolado, estrutura de ácido nucleico, método para tratamento de doença ou condição associada ao excesso de glutamato, e método de purificação de um polipeptídeo
BR112022006923A2 (pt) Polipeptídeos recombinantes para localização celular regulável
BR112023022319A2 (pt) Anticorpos anti-tigit, anticorpos anti-cd96 e métodos de uso dos mesmos
Ramírez-Carreto et al. Identification of a pore-forming protein from sea anemone Anthopleura dowii Verrill (1869) venom by mass spectrometry
BR112021019139A2 (pt) Célula de mamífero manipulada, composição, molécula isolada de dna de fita dupla, dispositivo implantável, cápsula de hidrogel, e, método de tratamento de um paciente com doença de fabry
BR112022000954A2 (pt) Método para a produção de uma composição enzimática compreendendo uma endopeptidase recombinante
BR112023022367A2 (pt) Anticorpos anti-tigit e métodos de uso dos mesmos
Wu et al. Curcumin-induced acute generalized exanthematous pustulosis
Kwan et al. Proteomic profiling of freeze-and spray-dried water extracts of snakehead fish (Channa striatus): In search of biomolecules for wound healing Properties
BR112022022615A2 (pt) Proteína nova e usos terapêuticos e cosméticos da mesma